Core Laboratories Inc. (NYSE:CLB - Free Report) - Zacks Research raised their Q2 2027 earnings per share (EPS) estimates for shares of Core Laboratories in a research note issued to investors on Tuesday, July 8th. Zacks Research analyst R. Department now forecasts that the oil and gas company will post earnings per share of $0.26 for the quarter, up from their previous estimate of $0.25. The consensus estimate for Core Laboratories' current full-year earnings is $0.96 per share.
A number of other research firms have also commented on CLB. Stifel Nicolaus reduced their price objective on Core Laboratories from $19.00 to $15.00 and set a "hold" rating on the stock in a research note on Tuesday, April 15th. Citigroup reduced their price objective on Core Laboratories from $16.00 to $13.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Finally, Wall Street Zen lowered Core Laboratories from a "hold" rating to a "sell" rating in a research note on Friday, April 25th. Two research analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $15.00.
View Our Latest Report on CLB
Core Laboratories Price Performance
Core Laboratories stock opened at $12.92 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.64 and a current ratio of 2.21. The firm has a market cap of $605.69 million, a P/E ratio of 21.90, a P/E/G ratio of 3.87 and a beta of 1.41. The business's fifty day moving average is $11.81 and its two-hundred day moving average is $14.32. Core Laboratories has a 52 week low of $10.14 and a 52 week high of $25.13.
Core Laboratories (NYSE:CLB - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The oil and gas company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Core Laboratories had a return on equity of 15.06% and a net margin of 5.41%. The firm had revenue of $123.59 million for the quarter, compared to analyst estimates of $125.09 million. During the same period in the previous year, the business posted $0.19 EPS. Core Laboratories's revenue for the quarter was down 4.7% compared to the same quarter last year.
Core Laboratories Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Tuesday, May 27th. Stockholders of record on Monday, May 5th were given a dividend of $0.01 per share. The ex-dividend date was Monday, May 5th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.31%. Core Laboratories's payout ratio is currently 6.78%.
Institutional Investors Weigh In On Core Laboratories
A number of institutional investors and hedge funds have recently made changes to their positions in CLB. Smartleaf Asset Management LLC increased its holdings in Core Laboratories by 173.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,037 shares of the oil and gas company's stock valued at $35,000 after purchasing an additional 1,293 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in Core Laboratories by 10.6% in the fourth quarter. Jones Financial Companies Lllp now owns 16,383 shares of the oil and gas company's stock valued at $284,000 after purchasing an additional 1,569 shares during the last quarter. Assetmark Inc. acquired a new position in Core Laboratories in the fourth quarter valued at about $26,000. Raymond James Financial Inc. acquired a new position in Core Laboratories in the fourth quarter valued at about $6,760,000. Finally, Amundi grew its stake in Core Laboratories by 194.8% in the fourth quarter. Amundi now owns 32,968 shares of the oil and gas company's stock valued at $600,000 after acquiring an additional 21,783 shares during the period. Institutional investors own 97.81% of the company's stock.
About Core Laboratories
(
Get Free Report)
Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Core Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Core Laboratories wasn't on the list.
While Core Laboratories currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.